Plasma Oxidized Low-Density Lipoprotein Levels and Arterial Stiffness in Older Adults
The Health, Aging, and Body Composition Study


Abstract—Arterial stiffness is a prominent feature of vascular aging and is strongly related to cardiovascular disease. Oxidized low-density lipoprotein (ox-LDL), a key player in the pathogenesis of atherosclerosis, may also play a role in arterial stiffening, but this relationship has not been well studied. Thus, we examined the cross-sectional association between ox-LDL and aortic pulse wave velocity (aPWV), a marker of arterial stiffness, in community-dwelling older adults. Plasma ox-LDL levels and aPWV were measured in 2295 participants (mean age: 74 years; 52% female; 40% black) from the Health, Aging, and Body Composition Study. Mean aPWV significantly increased across tertiles of ox-LDL (tertile 1: 869±376 cm/s; tertile 2: 901±394 cm/s; tertile 3: 938±415 cm/s; \( P=0.002 \)). In multivariate analyses, ox-LDL remained associated with aPWV after adjustment for demographics and traditional cardiovascular disease risk factors (\( P=0.008 \)). After further adjustment for hemoglobin A1c, abdominal visceral fat, antihypertensive and antilipemic medications, and C-reactive protein, the association with ox-LDL was attenuated but remained significant (\( P=0.01 \)). Results were similar when ox-LDL was expressed in absolute (milligrams per deciliter) or relative amounts (percentage of low-density lipoprotein). Moreover, individuals in the highest ox-LDL tertile were 30% to 55% more likely to have high arterial stiffness, defined as aPWV >75th percentile (\( P=0.02 \)). In conclusion, we found that, among elderly persons, elevated plasma ox-LDL levels were associated with higher arterial stiffness, independent of cardiovascular disease risk factors. These data suggest that ox-LDL may be related to the pathogenesis of arterial stiffness. (Hypertension. 2009;53:846-852.)

Key Words: aging ■ epidemiology ■ arterial stiffness ■ pulse wave velocity ■ oxidative stress

Arterial stiffening, one of the most significant manifestations of vascular aging, is a complex process involving extracellular matrix proteins and smooth muscle cells.\(^1\)\(^2\) Arterial stiffness has traditionally been linked to structural alterations in the vascular wall, including fragmentation and degeneration of elastin, increases in collagen content, arterial wall thickening, and luminal dilation. These age-related changes have adverse effects on cardiovascular health, for arterial stiffness increases systolic and pulse pressures, promotes left ventricular hypertrophy and dysfunction, and impairs coronary blood flow.\(^3\)^\(^4\) Moreover, increased arterial stiffness is associated with increased risk for cardiovascular disease (CVD) and its sequelae, including heart failure, stroke, atherosclerosis, myocardial infarction, and mortality.\(^1\)^\(^3\)^\(^5\)--\(^10\)

Although the exact mechanisms underlying arterial stiffening are not well understood, the imbalance in oxidants and antioxidants, in favor of the former (ie, oxidative stress) may play an important role. Oxidative stress contributes to vascular dysfunction and has been implicated in the pathogenesis of aging, atherosclerosis, diabetes mellitus, hypertension, and hypercholesterolemia.\(^1\)\(^1\) The oxidative modification of low-density lipoprotein (LDL) is recognized as a key step in the initiation and progression of atherosclerosis,\(^1\)\(^2\) and elevated circulating levels of oxidized LDL (ox-LDL; a marker of oxidative stress) are associated with CVD risk factors, eg, blood pressure, fasting glucose, and lipid levels, as well as both clinical and subclinical CVDs.\(^1\)\(^3\)--\(^15\) Thus, ox-LDL may be a marker of pathological processes occurring in the vascular wall.

Limited evidence suggests that ox-LDL is associated with the development of arterial stiffness. Ox-LDL stimulates collagen synthesis in arterial smooth muscle cells,\(^1\)\(^6\) promotes...
intimal thickening,17 and impairs NO bioactivity.18–20 all of which may contribute to arterial stiffness. In addition, circulating ox-LDL levels are inversely associated with arterial elasticity in young men21 and aortic stiffness in middle-aged men.22 However, it is not clear whether the association holds true in elderly men and women who likely have significant increases in both ox-LDL and arterial stiffness, as well as multiple comorbidities. Thus, the purpose of this study was to examine the association between plasma ox-LDL levels and arterial stiffness in a community-based sample of older adults.

Methods

Subjects

The present study uses data from the Health, Aging, and Body Composition (Health ABC) Study, a prospective cohort study of 3075 well-functioning black and white men and women aged 70 to 79 years. Participants were recruited from a random sample of white and all black Medicare beneficiaries from March 1997 to July 1998 at field centers in Memphis and Pittsburgh. Eligible participants reported no difficulty walking one quarter of a mile, climbing 10 steps, or performing basic activities of daily living. Participants were excluded if they were being actively treated for cancer, planned to move from the area within 3 years, or were participating in a trial involving a lifestyle intervention. All of the participants signed a written informed consent form that was approved by the institutional review boards of the University of Pittsburgh and the University of Tennessee. All of the procedures followed were in accordance with institutional guidelines. Aortic pulse wave velocity (aPWV) data were missing for 354 participants because of equipment problems, and 233 participants had waveforms that were of unacceptable quality or out of range (<300 or >3000 cm/s). Another 23 participants were excluded because of missing data on ox-LDL levels. An additional 170 participants were excluded because of missing data on pertinent covariates. Thus, the present study uses data from the remaining 2295 participants. The 780 participants who were excluded were more likely to be black (47% versus 40%) and diabetic (18% versus 14%), have lower systolic blood pressure (SBP; 134 versus 136 mm Hg), and have higher abdominal visceral fat (153 versus 140 cm²).

Oxidized LDL

Plasma levels of ox-LDL were measured using a monoclonal antibody (4E6)-based competition ELISA, as described previously.13 The monoclonal antibody 4E6 is directed against a conformational modification of apolipoprotein B-100 in the absence of the peroxidation of LDL lipids. The high specificity of this assay has been described previously.13 The interassay coefficient of variation for the monoclonal antibody 4E6 is 12%.

Aortic Pulse Wave Velocity

aPWV was measured from simultaneous Doppler flow signals obtained from the right carotid and femoral arteries with nondirectional transcutaneous Doppler flow probes (model 810A, 9.0- to 10-MHz probes, Parks Medical Electronics, Inc). Digitized data were recorded by custom programming for subsequent analysis. A minimum of 10 beats were averaged for each simultaneous recording site using the QRS for synchronization. Three separate runs were recorded for each participant, and all of the usable runs were averaged. The distance between the carotid and femoral sampling sites was measured above the surface of the body with a metal tape measure in 3 sections: from the site of the carotid probe to the second intercostal space, from the second intercostal space to the umbilicus, and from the umbilicus to the site of the femoral probe. All 3 of the distances were summed, and then the distance from the carotid probe to the second intercostal space was subtracted twice. This accounts for the fact that the flow from the heart to the carotid artery is in the opposite direction of the flow from the heart to the femoral artery. The time differentials between the onset of flow at carotid and femoral sites were divided by the associated distance to produce flow velocity. Stiffer vessels are associated with a faster PWV. The National Institute on Aging, Laboratory of Cardiovascular Science, Gerontology Research Center, trained and certified all of the study personnel before data collection, read the waveforms, and evaluated data quality. Results from all of the acceptable runs were averaged for the final aPWV measure used in the analyses. Replicate measures of aPWV in 14 subjects revealed intraclass correlations of 0.88 between sonographers and 0.84 between readers.

Medical History and Clinical Measurements

Prevalent hypertension, diabetes mellitus, and CVD were evaluated by questionnaire and confirmed by use of specific medications or procedures. Prevalent CVD was defined as a history of myocardial infarction, angina, stroke, transient cerebral ischemia, or any vascular surgery, including endarterectomy or angioplasty. Medications taken in the past 2 weeks were brought in, recorded, and coded according to the Iowa Drug Information System. Using this system, participants using antilipemic and antihypertensive medications were identified. Blood pressure was measured 3 times using a conventional mercury sphygmomanometer with participants in the seated position after 5 minutes of quiet rest. The average of the last 2 measurements was used for SBP and diastolic blood pressure (DBP). Body mass index (BMI) was calculated from measured weight and height. Abdominal visceral fat was measured using a single 1-cm computed tomography image obtained during suspended respiration between the fourth and fifth lumbar vertebrae. Physical activity in the previous 7 days was assessed using an interviewer-administered questionnaire, and participants were categorized into 3 groups according to their overall physical activity pattern: inactive (ie, <1000 kcal/wk of exercise activity and >2719 kcal/wk of total physical activity based on the Surgeon General’s recommendation and the 25th percentile for the Health ABC cohort, respectively); lifestyle active (ie, <1000 kcal/wk of exercise activity and >2719 kcal/wk of total physical activity); and exercise (ie, ≥1000 kcal/wk of exercise).23

Laboratory Measures

Total and high-density lipoprotein (HDL) cholesterol, serum triglycerides, and glucose levels were measured on a Johnson & Johnson Vitros 950 analyzer. HDL was assayed after a magnetic precipitation of LDL, very LDL, and chylomicrons. LDL was estimated with the Friedewald equation.24 Fasting glucose levels were measured using an automated glucose oxidase reaction (YSI 2300 Glucose Analyzer; YSI). C-reactive protein (CRP) was measured by an ELISA based on purified human protein and polyclonal anti-CRP antibodies (Diagnostics). Hemoglobin A1c was measured by a fully automated analyzer (Variant; Bio-Rad Laboratories, Inc) based on the principle of ion-exchange high-performance liquid chromatography.

Statistical Analysis

aPWV and ox-LDL were not normally distributed and were normalized through a log transformation. Other variables that were log transformed for analysis included HDL cholesterol, triglycerides, fasting glucose, hemoglobin A1c, and CRP. χ² tests and ANOVA were used to evaluate associations between tertiles of ox-LDL and categorical and continuous variables, respectively. Tertile definitions were as follows: tertile 1: 0.12 to 0.91 mg/dL; tertile 2: 0.91 to 1.34 mg/dL; and tertile 3: 1.34 to 7.31 mg/dL. Multivariate regression analyses were used to determine the relationship between arterial
stiffness and ox-LDL (expressed in absolute amounts as milligrams per deciliter or in relative amounts as the percentage of LDL). We also examined the association of the ox-LDL tertile with high arterial stiffness (defined as aPWV >75th percentile). A value of P≤0.05 was considered statistically significant. SAS 9.1 (SAS Institute) was used for all of the analyses.

## Results

Of the 2295 participants used in this analysis, 52% were women and 40% were black. The mean (SD) age was 73.7 (2.8) years. Ox-LDL values ranged from 0.12 to 7.31 mg/dL, with a mean (SD) of 1.27 (0.69) mg/dL and a median (interquartile range) of 1.10 (0.83 to 1.52) mg/dL. When expressed as a percentage of LDL, ox-LDL values ranged from 0.08% to 10.2%, with a mean (SD) of 1.06% (0.51%) and a median (interquartile range) of 0.96% (0.75% to 1.23%). Other subject characteristics by tertile of ox-LDL (milligrams per deciliter) are shown in Table 1. In general, individuals in the highest tertile of ox-LDL were more likely to be women (P=0.05), black (P<0.0001), and have hypertension (P=0.05) and diabetes mellitus (P=0.05) and were

<table>
<thead>
<tr>
<th>Characteristic</th>
<th>Tertile 1 (0.12 to 0.91)</th>
<th>Tertile 2 (0.91 to 1.34)</th>
<th>Tertile 3 (1.34 to 7.31)</th>
<th>P</th>
</tr>
</thead>
<tbody>
<tr>
<td>Age, y</td>
<td>73.8±2.9</td>
<td>73.7±2.8</td>
<td>73.6±2.9</td>
<td>0.56</td>
</tr>
<tr>
<td>Female</td>
<td>384 (50.5)</td>
<td>386 (50.2)</td>
<td>427 (55.8)</td>
<td>0.05</td>
</tr>
<tr>
<td>Black</td>
<td>266 (35.0)</td>
<td>299 (38.9)</td>
<td>353 (46.1)</td>
<td>&lt;0.0001</td>
</tr>
<tr>
<td>Smoking</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Never</td>
<td>327 (43.0)</td>
<td>333 (43.3)</td>
<td>359 (46.9)</td>
<td>0.53</td>
</tr>
<tr>
<td>Former</td>
<td>358 (47.0)</td>
<td>355 (46.2)</td>
<td>332 (43.4)</td>
<td></td>
</tr>
<tr>
<td>Current</td>
<td>75 (10.0)</td>
<td>81 (10.5)</td>
<td>74 (9.7)</td>
<td></td>
</tr>
<tr>
<td>Physical activity</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Inactive</td>
<td>152 (20.0)</td>
<td>166 (21.6)</td>
<td>172 (22.5)</td>
<td>0.79</td>
</tr>
<tr>
<td>Lifestyle active</td>
<td>360 (47.3)</td>
<td>357 (46.4)</td>
<td>358 (46.8)</td>
<td></td>
</tr>
<tr>
<td>Exercise</td>
<td>249 (32.7)</td>
<td>246 (32.0)</td>
<td>235 (30.7)</td>
<td></td>
</tr>
<tr>
<td>Hypertension</td>
<td>310 (40.7)</td>
<td>338 (44.0)</td>
<td>359 (46.9)</td>
<td>0.05</td>
</tr>
<tr>
<td>Diabetes mellitus</td>
<td>90 (11.8)</td>
<td>124 (16.1)</td>
<td>113 (14.8)</td>
<td>0.05</td>
</tr>
<tr>
<td>CVD</td>
<td>173 (22.7)</td>
<td>207 (26.9)</td>
<td>178 (23.3)</td>
<td>0.12</td>
</tr>
<tr>
<td>Antilipemic drugs</td>
<td>141 (18.5)</td>
<td>112 (14.6)</td>
<td>94 (12.3)</td>
<td>0.003</td>
</tr>
<tr>
<td>Antihypertensive drugs</td>
<td>400 (52.6)</td>
<td>417 (54.2)</td>
<td>433 (56.6)</td>
<td>0.28</td>
</tr>
<tr>
<td>Total cholesterol, mg/dL</td>
<td>183±32</td>
<td>201±33</td>
<td>226±37</td>
<td>&lt;0.0001</td>
</tr>
<tr>
<td>HDL cholesterol, mg/dL</td>
<td>58±18</td>
<td>55±17</td>
<td>52±14</td>
<td>&lt;0.0001</td>
</tr>
<tr>
<td>LDL cholesterol, mg/dL</td>
<td>101±28</td>
<td>120±28</td>
<td>144±33</td>
<td>&lt;0.0001</td>
</tr>
<tr>
<td>Triglycerides, mg/dL</td>
<td>120±54</td>
<td>131±62</td>
<td>151±70</td>
<td>&lt;0.0001</td>
</tr>
<tr>
<td>Fasting glucose, mg/dL</td>
<td>99.3±31.0</td>
<td>104.9±34.9</td>
<td>107.4±34.7</td>
<td>&lt;0.0001</td>
</tr>
<tr>
<td>Hemoglobin A1c, %</td>
<td>6.1±1.0</td>
<td>6.4±1.2</td>
<td>6.5±1.1</td>
<td>&lt;0.0001</td>
</tr>
<tr>
<td>CRP, mg/L</td>
<td>2.96±5.75</td>
<td>2.68±3.76</td>
<td>3.26±4.94</td>
<td>&lt;0.0001</td>
</tr>
<tr>
<td>SBP, mm Hg</td>
<td>135.3±20.2</td>
<td>135.6±20.3</td>
<td>138.1±21.6</td>
<td>0.02</td>
</tr>
<tr>
<td>DBP, mm Hg</td>
<td>71.2±11.8</td>
<td>71.6±11.7</td>
<td>73.0±10.8</td>
<td>0.005</td>
</tr>
<tr>
<td>BMI, kg/m²</td>
<td>26.5±4.5</td>
<td>27.4±4.6</td>
<td>28.2±4.8</td>
<td>&lt;0.0001</td>
</tr>
<tr>
<td>Abdominal visceral fat, cm²</td>
<td>130±66</td>
<td>142±65</td>
<td>147±65</td>
<td>&lt;0.0001</td>
</tr>
<tr>
<td>Aortic PWV, cm/s</td>
<td>869±376</td>
<td>901±394</td>
<td>938±415</td>
<td>0.002</td>
</tr>
</tbody>
</table>

Data are mean±SD or numbers (frequencies).
Table 2. Relationship Between Log (ox-LDL) and Log (aPWV)

<table>
<thead>
<tr>
<th>Model</th>
<th>β±SE</th>
<th>P</th>
<th>Log Ox-LDL, mg/dL</th>
<th>β±SE</th>
<th>P</th>
<th>Log Ox-LDL, % of LDL</th>
</tr>
</thead>
<tbody>
<tr>
<td>1</td>
<td>0.063±0.017</td>
<td>0.0003</td>
<td>0.092±0.020</td>
<td>&lt;0.0001</td>
<td></td>
<td></td>
</tr>
<tr>
<td>2</td>
<td>0.085±0.020</td>
<td>&lt;0.0001</td>
<td>0.085±0.020</td>
<td>&lt;0.0001</td>
<td></td>
<td></td>
</tr>
<tr>
<td>3</td>
<td>0.053±0.020</td>
<td>0.008</td>
<td>0.053±0.019</td>
<td>0.006</td>
<td></td>
<td></td>
</tr>
<tr>
<td>4</td>
<td>0.049±0.019</td>
<td>0.01</td>
<td>0.052±0.019</td>
<td>0.008</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

Data are standardized regression coefficients for ox-LDL. Model 1: unadjusted; model 2: adjusted for age, gender, race, clinical site, and LDL cholesterol (when expressed as milligrams per deciliter only); model 3: adjusted for variables in model 2 plus smoking, physical activity, HDL cholesterol, triglycerides, fasting glucose, BMI, DBP, SBP, diabetes mellitus, and hypertension; and model 4: adjusted for variables in model 3 plus hemoglobin A1c, abdominal visceral fat, antilipemic and antihypertensive drug use, and CRP.

less likely to be on antilipemic medications (P=0.003). Higher plasma ox-LDL levels were also associated with higher total and LDL cholesterol, triglycerides, fasting glucose, hemoglobin A1c, CRP, SBP, DBP, BMI, and abdominal visceral fat and lower HDL cholesterol (all P<0.02). There were no differences in age, smoking, physical activity, prevalent CVD, or antihypertensive drug use between tertiles. Results were similar when ox-LDL was expressed as a percentage of LDL, except that higher relative amounts of ox-LDL were associated with lower amounts of total and LDL cholesterol and a higher prevalence of antihypertensive drug use. Ox-LDL (percentage of LDL) was not associated with antilipemic drug use.

As shown in Table 2, ox-LDL (milligrams per deciliter) was associated with aPWV in a univariate analysis (P=0.0003). This association remained significant after adjusting for demographic variables and LDL cholesterol (P<0.0001). To determine whether the association between ox-LDL and aPWV was independent of traditional CVD risk factors, we further adjusted for smoking, physical activity, diabetes mellitus, hypertension, BMI, blood pressure, fasting glucose, triglycerides, and HDL cholesterol. After adjustment for these risk factors, the association between ox-LDL and aPWV was attenuated but remained significant (P=0.0008). After additional adjustments for hemoglobin A1c, abdominal visceral fat, antihypertensive and antilipemic drug use, and CRP, the association with ox-LDL was further attenuated (P=0.01). Similar results were found when ox-LDL was expressed as the percentage of LDL. When we examined the unadjusted model using ox-LDL tertile, we found that individuals in the highest tertile had a significantly higher aPWV (geometric mean±SE: 871±1 cm/s) than individuals in the middle (832±1 cm/s; P=0.05) and lowest tertiles (813±1 cm/s; P=0.0005). In the fully adjusted model, aPWV remained significantly higher among individuals in the highest tertile compared with those in the lowest tertile (891±1 versus 851±1 cm/s; P=0.04).

Logistic regression was performed to study the relation of high arterial stiffness, defined as having aPWV values >75th percentile (>1054 cm/s), with ox-LDL. As shown in panel A of the Figure, individuals in the middle ox-LDL tertile (milligrams per deciliter) had a similar odds of having a high aPWV compared with individuals in the lowest tertile after adjusting for age, gender, race, site, smoking, LDL cholesterol, SBP, and abdominal visceral fat.

Discussion

The present study is the first epidemiological analysis to examine the relationship between ox-LDL and arterial stiffness in older persons. Our results showed that elevated plasma ox-LDL levels were associated with higher arterial stiffness, independent of demographics and traditional CVD risk factors. Previously in the Health ABC cohort, subjects with aPWV >641 cm/s (corresponding with the 25th percentile of the aPWV distribution) were found to have a >2-fold increase in the risk of CVD, a 2- to 3-fold increase in stroke, and a >50% increase in coronary heart disease events compared with those with values below this level. In keeping with these previous findings, we performed additional analyses to determine the effect of changing the definition of high arterial stiffness from aPWV values >1054 cm/s (75th percentile) to aPWV values >641 cm/s (25th percentile). We found that the association between ox-LDL and arterial stiffness remained essentially the same, regard-
Arterial stiffness increases with age, even in healthy individuals, mean plasma ox-LDL levels range from 0.57 to 1.48 mg/dL (0.48% to 1.25% of LDL). Similar levels were observed in our study population. The low plasma concentration is maintained, in part, by the presence of scavenger receptors on endothelial cells and specialized macrophages (ie, Kupffer cells) in the liver that are capable of rapidly clearing ox-LDL from the circulation. As such, increased levels of ox-LDL in plasma may reflect an impaired ability to remove modified lipoproteins from the circulation. Alternatively, higher levels may result from a reduced antioxidant capacity or an excessive production of oxidants. Elevated levels of ox-LDL are associated with coronary artery disease, acute coronary syndromes, myocardial infarction, intima-media thickness, plaque occurrence in the carotid and femoral arteries, coronary artery calcification, metabolic abnormalities, and inflammatory cytokines. Our data demonstrate that elevated ox-LDL levels are also associated with arterial stiffness. In fact, we found that persons with elevated ox-LDL levels were 30% to 55% more likely to have stiff arteries for their age than persons with low ox-LDL levels. Thus, plasma ox-LDL levels may be a marker of oxidative stress and the associated pathologic changes that occur in the vascular wall, independent of the effects of dyslipidemia, hyperglycemia, hypertension, or inflammation.

Arterial stiffness, which predominantly affects the aorta and proximal elastic arteries, is one of the cardinal manifestations of vascular aging. Arterial stiffness can impair the ability of the vascular system to distribute blood from the heart as steady flow through the peripheral capillaries and, thus, can have a devastating effect on the heart and microcirculation, especially in the brain and kidneys. The 2 major direct consequences of arterial stiffening are a reduced capacitance and a faster PWV, both of which can modify central hemodynamics. Arterial stiffness can increase SBP, and because of the rapid PWV, the reflected wave returns during systole rather than during diastole, thereby amplifying SBP even further and imposing an additional workload on the heart. Early return of wave reflection can also reduce DBP, thereby limiting coronary blood flow and predisposing to ischemia and angina. Increased arterial stiffness, along with the associated increases in SBP and pulse pressure, has been linked to a higher risk for developing heart failure, stroke, atherosclerosis, and myocardial infarction. Moreover, arterial stiffness has been associated with increased left ventricular hypertrophy and dysfunction as well as increased all-cause and cardiovascular mortality.

Arterial stiffness increases with age, even in healthy individuals without clinical CVD. The presence of CVD risk factors, eg, obesity or hypertension, may accelerate vascular changes that result in arterial stiffening. The underlying mechanisms remain to be elucidated; however, oxidative stress, or the imbalance in oxidants and antioxidants, in favor of the former, may play an important role. Oxidative stress can cause oxidative damage to lipids, proteins, DNA, and other biological molecules that are critical for normal cellular functioning. Accordingly, oxidative stress contributes to vascular dysfunction and has been implicated in the pathogenesis of hypercholesterolemia, atherosclerosis, hypertension, diabetes mellitus, and heart failure.

There is strong evidence to support a role for ox-LDL in the pathogenesis of arterial stiffening via changes in both the structure and function of the arterial wall. For example, ox-LDL increases the expression of matrix metalloproteinases in macrophages and endothelial cells, which may promote the breakdown of extracellular matrix components and contribute to vascular remodeling. Ox-LDL–mediated vascular remodeling is also characterized by an inflammatory and fibroproliferative response that leads to intimal thickening. This occurs, in part, from ox-LDL–induced endothelial cell activation, leukocyte adhesion, smooth muscle cell migration and proliferation, and increased collagen synthesis. The ox-LDL–induced expression of genes that facilitate vascular calcification may also contribute to stiffer arteries. Moreover, the capacitance of the arterial system may become compromised, for ox-LDL also induces endothelial dysfunction by impairing endothelium-dependent vasodilation, inhibiting NO bioavailability, and reducing endothelial NO synthase expression and activity.

Several limitations of the present study need to be considered. First, because this study was cross-sectional, we cannot determine whether increased ox-LDL is a cause of arterial stiffening or simply a byproduct of other disease processes. Second, although there is strong in vitro evidence supporting a role for ox-LDL in the development of vascular changes that promote arterial stiffness, this study cannot determine how or where the oxidation occurred, nor can we identify the mechanisms by which plasma ox-LDL may be related to arterial stiffness. Third, the oxidative modification of LDL leads to a heterogeneous population of ox-LDL particles with a variety of oxidized products and diverse biological properties. Thus, it is difficult to quantify the full range of oxidatively modified LDL particles in plasma. However, the 4E6 antibody used to measure ox-LDL in the present study has been well characterized and appears to be clinically useful in the assessment of oxidative stress and disease status in various populations. Fourth, it is possible that residual confounding from either unmeasured or imperfectly measured variables could explain the observed association.

Perspectives

This study demonstrates for the first time that plasma ox-LDL levels are related to arterial stiffness in elderly men and women. Our data suggest that the oxidative modification of LDL may be associated with changes in the elastic properties of blood vessels. As such, reducing oxidative stress is an attractive therapeutic target in the prevention of age-related changes in arterial structure and function and subsequent disease. Although antioxidant supplementation trials have been found to be largely ineffective in preventing cardiovascular outcomes, other interventions, including aerobic exer-
cise training and pharmaceutical treatment with lipid- and blood pressure-lowering medications, may have significant antioxidant effects that are related to reductions in CVD risk.

In understanding the relationship between oxidative stress and CVD, it is important to remember that free radicals and other oxidants are involved in both normal and pathological processes, and, therefore, manipulating cellular redox pathways could potentially cause harm. Thus, more research is needed to determine whether oxidative stress is a cause or a consequence of the disease process. Moreover, it is critical that researchers identify the major oxidants involved and if and how antioxidant therapies can be used to slow arterial stiffening with age and to prevent cardiovascular events.

Sources of Funding

This research was supported by grants N01-AI-6 to 2101, N01-AG-6-2103, N01-AG-6-2106, and R01-AG-027529-01A1S1. This research was also supported in part by the Intramural Research Program of the National Institutes of Health, National Institute on Aging.

Disclosures

None.

References


34. Pini R, Cavallini MC, Bencini F, Silvestrini G, Tonom E, De AW, Marchiorni N, Di BM, Devereux RB, Masotti G, Roman MF. Cardio-


Plasma Oxidized Low-Density Lipoprotein Levels and Arterial Stiffness in Older Adults: The Health, Aging, and Body Composition Study

for the Health, Aging, and Body Composition Study

Hypertension. 2009;53:846-852; originally published online March 30, 2009;
doi: 10.1161/HYPERTENSIONAHA.108.127043

Hypertension is published by the American Heart Association, 7272 Greenville Avenue, Dallas, TX 75231
Copyright © 2009 American Heart Association, Inc. All rights reserved.
Print ISSN: 0194-911X. Online ISSN: 1524-4563

The online version of this article, along with updated information and services, is located on the World Wide Web at:
http://hyper.ahajournals.org/content/53/5/846

Permissions: Requests for permissions to reproduce figures, tables, or portions of articles originally published in Hypertension can be obtained via RightsLink, a service of the Copyright Clearance Center, not the Editorial Office. Once the online version of the published article for which permission is being requested is located, click Request Permissions in the middle column of the Web page under Services. Further information about this process is available in the Permissions and Rights Question and Answer document.

Reprints: Information about reprints can be found online at:
http://www.lww.com/reprints

Subscriptions: Information about subscribing to Hypertension is online at:
http://hyper.ahajournals.org//subscriptions/